KyungDong Pharmaceutical is to start a Phase III trial on a combination drug consisting of a prostatomegaly treating agent tamsulosin and an overactive bladder treating agent mirabegron. The drug is expected to begin a commercialization race against Dongkoo Bio & Pharma that already received approval on Phase III trial.

Without any preceding combination drug with the two agents in the market, the patients would get to appreciate more convenient regimen if the drugs are successfully launched.

On Mar. 25, South Korea’s Ministry of Food and Drug Safety (MFDS) granted an approval on KyungDong Pharmaceutical’s 'KDF1905’ Phase III clinical trial protocol. The trial would use tamsulosin a